Buy Humatropes

Humatrope for sale – Buy real Humatrope HGH online

Humatrop is a drug based on the hormones of the anterior pituitary gland (HGH, somatropin). This is a biosynthetic recombinant human growth hormone with 191 amino acid residues in the polypeptide chain. It has somatotropic, anabolic and growth stimulating effects. The drug stimulates bone growth and causes an increase in the number and size of cells (in muscles, liver, thymus, adrenal glands, thyroid). This form of somatropin activates collagen synthesis, regulates protein metabolism, lowers cholesterol levels, increases the number of triglycerides, reduces the amount of adipose tissue and prevents the loss of fluid, nitrogen, sodium, potassium and phosphorus. [read more = ”Read more…” less = ”Read Less”]

Somatropin stimulates linear growth in children with Hgh deficiency and in children with growth retardation in Turner syndrome. Treatment of Hgh deficiency in children results in an increase in growth rate. In addition, somatropin improves intracellular protein synthesis and causes nitrogen retention.

Humatropic indications for use: disorders of the growth process in children with insufficient endogenous growth hormone production, chronic renal failure accompanied by growth disorders (in children), immunodeficiency disorders accompanied by weight loss, osteoporosis.

Information on Humatropic contraindications

Start studying Humatropic contraindications: hypersensitivity, malignant neoplasms, epiphyseal occlusion, acute conditions associated with complications after surgery or multiple injuries, pregnancy, breastfeeding.

Caution is advised in patients with diabetes mellitus or patients with a predisposition to diabetes. It is necessary to monitor glucose levels in the blood and urine. Patients with growth hormone deficiency need to be examined more frequently to rule out progression and recurrence of tumor growth.

Hypothyroidism may develop during treatment (the effectiveness of therapy may be reduced). A thorough examination of the fundus is recommended to detect papilla swelling (in case of recurrent headaches, visual disturbances, nausea, vomiting). In this case, Humatropic therapy must be discontinued (to exclude symptoms of intracranial hypertension).

It is not known whether recombinant somatropin affects reproductive function or whether it can cause fetal harm in pregnant women. Therefore, Humatrope should not be administered during pregnancy.

It is not known whether this medication fits into breast milk. Therefore, breastfeeding should be discontinued during Humatropic therapy.

Interaction with other drugs

Glucocorticoids reduce the stimulating effect of Humatrope on growth processes. Adequate doses should be carefully selected to prevent adrenal insufficiency.

Patients diagnosed with diabetes mellitus may need to adjust their insulin doses or other hypoglycemic agents.

Somatropin can increase the activity of cytochrome P450 isoenzymes (CYPs), which may lead to a decrease in the concentration and a decrease in the effectiveness of certain drugs such as steroid sex hormones, cyclosporins and some anticonvulsants.

Simultaneous therapy with other hormonal drugs (e.g. gonadotropins, anabolic steroids, estrogens and thyroid hormones) is not recommended.

Learn more about dosage and administration information for Humatrope

The medication is administered subcutaneously. Intramuscular injection is also permitted. The dose should be selected individually (up to 0.48 IU / kg per week).

Dosages for growth hormone deficiency: up to 0.48 IU / kg per week. Doses for Turner syndrome: 0.8-0.9 IU/kg. The weekly dose is divided into 6-7 injections and administered at night. During long-term therapy, it is necessary to control the concentration of glucose and thyroid hormones.

Learn more about the possible side effects of Humatrope

Common and rare side effects include: headache, increased intracranial pressure, frequent headaches, nausea, vomiting, visual disturbances, suppression of thyroid function (symptoms of hypothyroidism), hyperglycemia, leukemia, pain and itching at the injection site.

Immune system: hypersensitivity to the components of the drug, including allergic reactions.

Endocrine system: very often – hypothyroidism.

Metabolism: very common – swelling (in adults), hyperglycemia, including impaired glucose tolerance (in adults).

CNS: very often – headache; often – insomnia (in adults), carpal tunnel syndrome, paresthesia (in adults); rarely – benign intracranial hypertension, paresthesia (in children); very rarely – insomnia (in children).

Digestive disorders: rarely – pancreatitis.

Musculoskeletal system: very often – arthralgia (in adults); often – myalgia (in adults), scoliosis (in children); rarely – myalgia (in children).

Genitals and mammary gland: rarely – gynecomastia (in adults); very rarely – gynecomastia (in children).

General disorders: common – pain at the injection site; rarely – weakness, glucosuria (in adults); very rarely – glucosuria (in children).

Post-marketing surveillance:

Metabolism: rare – type 2 diabetes mellitus (in children).

Buy Humatropes

Vascular disorders: often – high blood pressure (in adults); very rarely – high blood pressure (in children).

Respiratory system: often – shortness of breath (in adults).

There are reports that a small number of children treated with somatropin (including Humatrope) suffered from leukemia. The direct connection between leukemia and treatment with somatropin is still unclear.

Symptoms of long-term toxicity (overdose): gigantism and acromegaly, hypersecretion of growth hormone, hypo- or hyperglycemia. Acute overdose may result first in hypoglycemia and then in hyperglycemia. Chronic overdose may cause signs and symptoms of gigantism or acromegaly.

Special instructions for Humatropic therapy

Humatropic therapy should be carried out by physicians experienced in the diagnosis and treatment of patients with GH deficiency or Turner syndrome.

Intracranial neoplasm. In patients with GH deficiency that occurred in the presence of brain neoplasms, more frequent examinations are recommended (to exclude progression and relapse of the disease). Somatropin should not be used if there are signs of active tumor growth. Antitumor therapy must be completed before you start taking Humatrope. The drug should be discontinued if signs of tumor growth occur.

Intracranial hypertension.Fundus examination is recommended for severe or recurrent headaches, visual disturbances, nausea, or vomiting (to rule out optic disc edema and intracranial hypertension). In this case, treatment with somatropin must be discontinued.

Hypopituitarism / hypothyroidism.Patients with hypopituitarism (deficiency of certain pituitary hormones) should be closely monitored in the event of standard hormone replacement therapy with somatropin. Note that hypothyroidism may occur during treatment with Humatrope.

Diabetes Mellitus.Humatrope can cause insulin resistance. Therefore, patients should be monitored for signs of impaired glucose tolerance. Patients with diabetes mellitus should be under constant medical supervision. The insulin dose may need to be adjusted during treatment with somatropin.

Older patients.Older patients are more sensitive to somatropin. Therefore, the risk of side effects is higher. It is advisable to use a smaller starting dose.

Obesity.The risk of adverse events is higher in patients with obesity.

Leukemia.A small group of children on GH therapy (including those using humatropes) had leukemia. The direct connection between leukemia and humatrope therapy has not been proven.

Scoliosis in children.Scoliosis is often diagnosed in children receiving GH therapy. Somatropin promotes bone growth. Therefore, patients using Humatrope should be monitored for scoliosis progression.

The risk of pancreatitis is higher in children treated with somatropin.

Somatropin therapy should only be prescribed by physicians experienced in treating children with growth disorders and adults with GH deficiency. [/Read]

Buy Humatrope individual evidence

1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021148s049lbl.pdf
2. https://www.deadiversion.usdoj.gov/drug_chem_info/hgh.pdf
3. https://medicalxpress.com/news/2007-01-proof-growth-hormone-therapy-longer.html
4. https://quackwatch.org/related/hgh/